DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations

Nucleic Acids Research

Volumn 35, Issue 13, 2007, Pages

  Hoffmann, Christian ^a   Minkah, Nana ^a   Leipzig, Jeremy ^a   Wang, Gary ^a   Arens, Max Q ^b   Tebas, Pablo ^a   Bushman, Frederic D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DNA; EMTRICITABINE; LAMIVUDINE; NELFINAVIR; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS DNA;

ALLELE; ARTICLE; CONTROLLED STUDY; FALSE POSITIVE RESULT; GENE AMPLIFICATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS MUTATION; ANTIBIOTIC RESISTANCE; CHEMISTRY; DNA SEQUENCE; DRUG EFFECT; EVALUATION; GENETICS; METHODOLOGY; MUTATION; STATISTICAL ANALYSIS;

ALLELES; ANTI-HIV AGENTS; DATA INTERPRETATION, STATISTICAL; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 34547829263     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkm435     Document Type: Article

References (21)

1. Clavel,F. and Hance,A.J. (2004) HIV drug resistance. See comment. N. Engl. J. Med., 350, 1023-1035.
2. Richman,D.D., Morton,S.C., Wrin,T., Hellmann,N., Berry,S., Shapiro,M.F. and Bozzette,S.A. (2004) The prevalence of antiretroviral drug resistance in the United States. AIDS, 18, 1393-1401.
3. Little,S.J., Holte,S., Routy,J.P., Daar,E.S., Markowitz,M., Collier,A.C., Koup,R.A., Mellors,J.W., Connick,E. et al. (2002) Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med., 347, 385-394.
4. Smith,D., Moini,N., Pesano,R, Cachay,E., Aiem,H., Lie,Y., Richman,D. and Little,S. (2007) Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. Clin. Infect. Dis., 44, 456-458.
5. Cane,P., Chrystie,I., Dunn,D., Evans,B., Geretti,A.M., Green,H., Phillips,A., Pillay,D., Porter,K. et al. (2005) Time trends in primary resistance to HIV drugs in the United Kingdom: Multicentre observational study. See comment. Br. Med. J., 331, 1368.
6. Mellors J, Palmer,S., Nissley D. Kearny M., Halvas E., Bixby C., Demeter L., Eshleman S., Bennett K., Hart S., Vaida F., Wantman M., Coffin J., Hammer S. (2004) Low-frequency NNRTI-resistant variants contribute to failure of efavirenz-containing regimen. In Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections Abstract 39.
7. Palmer,S., Kearney,M., Maldarelli,F., Halvas,E.K., Bixby,C.J., Bazmi,H., Rock,D., Falloon,J., Davey,R.T.Jr et al. (2005) Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol., 43, 406-413.
8. Jourdain,G., Ngo-Giang-Huong,N., Le Coeur,S., Bowonwatanuwong,C., Kantipong,P., Leechanachai,P., Ariyadej,S., Leenasirimakul,P., Hammer,S. et al. (2004) Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. See comment. N. Engl. J. Med., 351, 229-240.
9. LockmanS., Shapiro,R.L., Smeaton,L.M., Wester,C., Thior,I., Stevens,L., Chand,F., Makhema,J., Moffat,C. et al. (2007) Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N. Engl. J. Med., 356, 135-147.
10. Halvas,E.K., Aldrovandi,G.M., Balfe,P., Beck,I.A., Boltz,V.F., Coffin,J.M., Frenkel,L.M., Hazelwood,J.D., Johnson,V.A. et al. (2006) Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J. Clin. Microbiol., 44, 2612-2614.
11. Cai,F., Chen,H., Hicks,C.B., Bartlett,J.A., Zhu, J. and Gao,F. (2007) Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat. Methods, 4, 123-125.
12. Kozal,M.J., Shah,N., Shen,N., Yang,R., Fucini,R., Merigan,T.C., Richman,D.D., Morris,D., Hubbell,E. et al. (1996) Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat. Med., 2, 753-759.
13. O'Meara,D., Wilbe,K., Leitner,T., Hejdeman,B., Albert,J. and Lundeberg,J. (2001) Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. J. Clin. Microbiol., 39, 464-473.
14. Margulies,M., Egholm,M., Altman.W.E., Attiya,S., Bader,J.S., Bemben,L.A., Berka,J., Braverman,M.S., Chen,Y.J. et al. (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature, 437, 376-380.
15. Binladen,J., Gilbert,M.T., Bollback,J.P., Panitz,F., Bendixen,C., Nielsen,R. and Willerslev,E. (2007) The use of coded PCR primers enables high-throughput sequencing of multiple homolog amplification products by 454 parallel sequencing. PLoS ONE, 2, e197.
16. Shoemaker,D.D., Lashkari,D.A., Morris,D., Mittmann,M. and Davis,R.W. (1996) Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy. Nat. Genet., 14, 450-56.
17. Rhee,S.Y., Gonzales,M.J., Kantor,R., Betts,B.J., Ravela,J. and Shafer,R.W. (2003) Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res., 31, 298-303.
18. Johnson,V.A., Brun-Vezinet,F., Clotet,B., Conway,B., Kuritzkes,D.R., Pillay,D., Schapiro,J.M., Telenti,A. and Richman,D.D. (2005) Update of the drug resistance mutations in HIV-1: Fall 2005. Top. HIV Med., 13, 125-131.
19. Jagodzinski,L.L., Wiggins,D.L., McManis,J.L., Emery,S., Overhaugh,J., Robb,M., Bodrug,S. and Michael,N.L. (2000) Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests. J. Clin. Microbiol., 38, 1247-1249.
20. Kantor,R. and Katzenstein,D. (2004) Drug resistance in non-subtype B HIV-1. J. Clin. Virol., 29, 152-159.
21. Holguin,A., Paxinos,E., Hertogs,K., Womac,C. and Soriano,V. (2004) Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J. Clin. Virol., 31, 215-220.